Company / SG&A Expense
Coherus Oncology, Inc. SG&A Expense History
FY2014-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$137.0M
FY2019
5-year range
$7.5M / $137.0M
FY2015-FY2019
Trend
+45.5%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has increased for 5 consecutive years, from $6M in FY2014 to $137M in FY2019.
Based on SEC 10-K filings.
$137M in FY2019 with a 5-year CAGR of +90.0%.
Increased from $71M to $137M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +98.3%
- 5-Year CAGR
- +90.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- Coherus Oncology, Inc.'s sg&a expense has grown for 5 consecutive years.
- 5-year CAGR of +90.0%, indicating consistent growth.
- In FY2019, sg&a expense increased 45.5% year-over-year.
- Lowest sg&a expense in the period was in FY2014.
Company context
Key Data Points
- Altman Z-Score -0.49 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2019 | $137.0M | +45.5% |
| FY2018 | $94.2M | +32.1% |
| FY2017 | $71.3M | +306.0% |
| FY2016 | $17.6M | +135.3% |
| FY2015 | $7.5M | +35.0% |
| FY2014 | $5.5M | - |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026